Inhibrx Biosciences, Inc. (INBX)
| Market Cap | 1.37B +587.6% |
| Revenue (ttm) | 1.30M +550.0% |
| Net Income | -130.19M |
| EPS | -8.39 |
| Shares Out | 14.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,908 |
| Open | 95.12 |
| Previous Close | 92.20 |
| Day's Range | 91.60 - 96.09 |
| 52-Week Range | 13.97 - 155.29 |
| Beta | 3.32 |
| Analysts | Buy |
| Price Target | 277.50 (+197.49%) |
| Earnings Date | May 14, 2026 |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INBX stock is "Buy." The 12-month stock price target is $277.5, which is an increase of 197.49% from the latest price.
News
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventio...
Inhibrx price target raised to $325 from $300 at Stifel
Stifel raised the firm’s price target on Inhibrx (INBX) to $325 from $300 and keeps a Buy rating on the shares.
Inhibrx Reports First Quarter 2026 Financial Results
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical comp...
Inhibrx Biosciences Quarterly report: Q1 2026
Inhibrx Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
Inhibrx (INBX) Biosciences announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavale...
Inhibrx Biosciences Transcript: Study update
Interim phase II data show INBRX-106 plus pembrolizumab achieved a 44% ORR versus 21.4% for pembrolizumab alone in first-line PD-L1-positive head and neck cancer, with deeper and more complete responses and a manageable safety profile. Robust T cell activation supports further phase III development.
Inhibrx Biosciences Press release: Study update
Inhibrx Biosciences issued a press release on May 11, 2026, disclosing material business information to investors.
This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.
Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab com...
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage bio...
Inhibrx initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Inhibrx (INBX) with an Outperform rating and $200 price target
Inhibrx Biosciences Proxy statement: Proxy filing
Inhibrx Biosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Inhibrx Biosciences Proxy statement: Proxy filing
Inhibrx Biosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Inhibrx price target raised to $300 from $150 at Stifel
Stifel analyst Dara Azar raised the firm’s price target on Inhibrx (INBX) to $300 from $150 and keeps a Buy rating on the shares. Ahead of key trial data for…
Inhibrx trading halted, volatility trading pause
09:33 EDT Inhibrx (INBX) trading halted, volatility trading pause
Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says
Inhibrx (INBX) Biosciences’ INBRX-106 cancer drug is drawing interest from Merck (MRK) and Japan’s Ono Pharmaceuticals, Reuters reports, citing people familiar with the matter. The company is explorin...
Inhibrx up 39% at $117 after report of interest from Merck in cancer assets
08:08 EDT Inhibrx (INBX) up 39% at $117 after report of interest from Merck in cancer assets
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more tha...
Inhibrx Biosciences Transcript: Study update
Ozekibart plus FOLFIRI showed a 20% ORR and 5.5-month median PFS in late-line CRC, with durable responses and a favorable safety profile. Plans are underway for first-line registrational trials and expansion into earlier lines and other tumor types.
Inhibrx Biosciences Press release: Study update
Inhibrx Biosciences issued a press release on April 21, 2026, disclosing material business information to investors.
Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart
Inhibrx (INBX) Biosciences announced updated interim data from its Phase 1/2 study evaluating ozekibart, or INBRX-109, in combination with FOLFIRI in patients with locally advanced or metastatic, unre...
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therape...
Inhibrx Biosciences Slides: Investor presentation
Inhibrx Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT – SAN DIEGO, April 20, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-sta...